An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

One of the biggest challenges in cancer treatment is addressing the ability of cancer cells to adapt and become resistant, ...

Aethlon is trading up today, currently at $0.6930, up 0.0700, gaining 11.1643% on over 2.1 Million shares. The stock has a ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...

Explore the role of the extracellular matrix (ECM) in prostate cancer progression and discover natural therapies, including ...

A major breakthrough in the fight against cancer has just been achieved. An innovative method, successfully tested in the ...

Scientists from the University of Pennsylvania have developed an innovative cancer treatment using small extracellular ...

Researchers at the University of Pennsylvania have introduced lab-engineered small extracellular vesicles to target tumors in ...

37 Natural killer group 2 member D ligands are stress-induced molecules expressed on the surface of tumor cells, including CRC. 43 Targeting them with CAR-T cells can enhance the immune response ...

1月23日，东南大学生命科学与技术学院、东南大学附属中大医院肿瘤科高山教授团队在Proceedings of the National Academy of Science of the United States of ...